- Effectiveness and Utility of SRT-100™ Demonstrated in the Companion-Animal Market
- Best-in-class localization features of SRT-100 enable new radiation therapy options in veterinary settings
BOCA RATON, Fla, March 16, 2021 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today that the first canine patient was successfully treated with the company’s SRT-100™ system. SRT-100 systems utilize Sensus Healthcare’s proprietary low-energy x-ray technology known as superficial radiation therapy (SRT) that enables radiation therapy to target harder-to-reach lesions, such as those often found in animal patients.
The canine, an American bulldog, named Daisy, was treated at Flint Animal Cancer Center at the Colorado State University (CSU) James L. Voss Veterinary Teaching Hospital. Daisy was the first canine patient anywhere to be treated with the SRT-100. The agreement with the school calls for the development of protocols for SRT use and the publishing of clinical data.
Daisy was diagnosed with two small mast cell tumors, one on her muzzle and the other on her lower eyelid. Following six treatments supported by SRT-100, there was a reduction in the size of both masses, negating the need for surgery, with hair loss being the only notable side effect.
“This was the first opportunity we had to employ the Sensus Healthcare device. In the past, we have been limited with our treatment options, especially when the tumors were too small or unreachable for traditional radiation therapies, as was the case with Daisy,” said Dr. Tiffany Martin, radiation oncologist at the Flint Animal Cancer Center. “We expect to see a growing use of this technology to treat other superficial skin or oral cancers, potentially alongside intraoperative surgery to treat questionable surgical margins.”
John Heinrich, Ph.D., a member of the Sensus Healthcare board of directors and the key relationship contact with CSU, added, “We are pleased to hear of Daisy’s recovery and of the groundbreaking work by the team of oncologists and veterinarians at Colorado State University Veterinary Teaching Hospital. Their work affirms the importance of our partnerships and how they continually expand our application potential and demonstrate the critical role of the SRT-100 in the treatment landscape.”
SRT-100 is used by dermatologists in human medicine to treat non-melanoma skin lesions, including basal cell and squamous cell carcinomas. The SRT-100 from Sensus Healthcare is being used to explore possible applications in veterinary medicine, which represents a potential new market for Sensus.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted Directional Anisotropic Radiation Therapy (ART) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
LHA Investor Relations
Kim Sutton Golodetz
# # #
Coinsmart. Beste Bitcoin-Börse in Europa
New York Bone & Joint Specialists: New Invention Stops or Delays the Progression of Osteoarthritis of the Knee
Ping An AskBob Doctor’s Smart Imaging Model for Diagnosis of Pelvic and Hip Injuries is a Breakthrough for Artificial Intelligence
April 1, 2021
Ping An Insurance (Group) Company of China, Ltd. “Ping An” announced that Ping An AskBob Doctor’s smart imaging model for diagnosing pelvic and hip injuries is the first of its kind to accurately detect all kinds of trauma-related findings simultaneously in X-ray images.
In a research paper published in the international journal Nature Communications, the model is shown to overcome the limitation of other artificial intelligence (AI) systems, which can only detect individual fractures.
The model, a deep learning algorithm, can help physicians make faster, more accurate diagnoses and save lives. Hip fractures mainly occur in elderly people and patients with major trauma. Although they are not directly fatal, complications can lead to a high mortality rate. Reducing the rate of missed diagnoses, improving the comprehensiveness of the detection, and providing accurate diagnoses is critical.
Ping An Health Technology Research Institute, Ping An Smart City, Ping An Good Doctor and the Department of Trauma and Emergency Surgery of Chang Gung Memorial Hospital in Taiwan jointly released the research paper “A scalable physician-level deep learning algorithm detects universal trauma on pelvic radiographs”. The research team gathered the pelvic X-ray data of 1,888 emergency room patients to evaluate the model’s performance in obtain the fracture results and locations. It achieved an overall accuracy of 92.4%. Compared with general clinical diagnoses, the model substantially improves detection accuracy, speeds up the treatment progress, improves the treatment effectiveness on high-risk patients, and reduces the economic cost to patients through earlier detection and treatment.
This is the first AI algorithm to detect all fracture types captured on the X-ray images, including, but not limited to, hip fractures, pelvic fractures, femoral fractures, hip dislocation and artificial joint peripheral fractures.
As of March, 2021, the AskBob Doctor AI pelvic trauma detection technology has been used in the real-life clinical environment in Chang Gung Memorial Hospital in Taiwan for nearly eight months. The results have shown that the misdiagnosis rate has significantly reduced. Since adopting the AI system, the misdiagnosis rate has dropped from 9.7% to 0.7% among emergency physicians, 11.3% to 1.58% among resident physicians and 6% to 0.5% among specialist physicians. The model has performed comparably to radiologists and certain orthopedic specialists in terms of quantitative indicators such as sensitivity and specificity.
The smart imaging model for the diagnosis of pelvis and hip injuries is Ping An’s latest achievement in smart imaging technology. Ping An’s smart imaging technology covers nine major systems of human body — the motor, digestive, respiratory, urinary, reproductive, endocrine, immune, nervous and cardiovascular systems. It supports various equipment including computed tomography (CT,) X-ray, ultrasound and fundus optical coherence tomography (OCT).
Sander de Vos Is Appointed Chief Business Officer of IME Medical
April 1, 2021
Sander de Vos will be responsible for the worldwide roll-out of the company’s medical electrospinning strategy, based on IME’s ground-breaking MediSpin™XL industrial production platform.
Judith Heikoop, CEO of IME Medical Electrospinning said, “We at IME are thrilled to welcome Sander to our fast-growing team of professionals. Sander clearly brings a wealth of well-needed life science experience into the company, that will certainly be of key-value to the further development of our electrospun medical device franchises. Our aim is to become the first partner of choice worldwide for the development of a novel, groundbreaking class of medical devices and pharma products based on nanofibers. Our ever-growing portfolio of customers and partners includes the Medtech and Pharma industry, universities, hospitals, and medical institutes.”
Sander de Vos (46) is an accomplished executive with more than 15 years of leadership experience across healthcare and biotech commercial and business development positions. Prior to joining IME, Sander worked at Mimetas, an innovative Dutch start-up company providing novel human cell biology models for improved therapies, where he played a key role in expanding the collaborations with its pharma and biotech partners.
In previous roles, Sander led the commercial team of Isogen Life Science and acquired experience as an entrepreneur growing a private business. His commercial career started at Westburg Life Sciences and for more than 10 years he shaped and directed the sales strategy and commercial development of part of their life science business.
Sander has a background in molecular biology, co-developed a molecular diagnostic test for simultaneous detection of tick-borne pathogens, and contributed to the development of a vaccine against ticks at the Faculty of Veterinary Medicine of the Utrecht University.
Sander de Vos, Chief Business Officer of IME Medical Electrospinning, said: “With the potential of becoming the global leader in large-scale production of best-in-class nanofiber based medical devices and drug delivery solutions, I’m proud, gratified and delighted to become a member of the IME management team. The company’s technology enables faster and better recovery of tissues and body structures, and therefore IME is uniquely positioned to make a meaningful difference in the lives of patients.”
Dipti Itchhaporia, MD, FACC: New American College of Cardiology President
April 1, 2021
Dipti Itchhaporia, MD, FACC, today begins her term as president of the American College of Cardiology.
During her one-year presidency, she will lead the over 54,000-member global organization in its mission to transform cardiovascular care and improve heart health.
“From the moment I became a Fellow of the ACC, I’ve been excited about being a part of this community and contributing to advancing the field of cardiology and the patients we serve,” Itchhaporia said. “I’m looking forward to connecting the cardiovascular community over the next year, as we emerge from a mostly virtual world, to make strides in our strategic priorities and improve the lives of heart disease patients. We must be prepared as a profession to embrace and move to center stage our solutions and vision of digital transformation and health equity.”
Itchhaporia is an interventional cardiologist who is the Eric and Sheila Samson Endowed Chair in Cardiovascular Health, director of disease management for Hoag’s Jeffrey M. Carlton Heart and Vascular Institute in Newport Beach, California, and associate professor of medicine at the University of California, Irvine. She has been a leader in the College for over 20 years, previously holding positions both nationally and in the ACC California Chapter.
Most recently, Itchhaporia held the position of ACC vice president. She previously served as a member of the ACC’s Board of Trustees and the Board of Governors, secretary of the ACC as chair of the Board of Governors, and president of the ACC California Chapter. She has also served on multiple ACC committees and helped to advance the College’s education, science and innovation efforts, including as a member of the ACC Lifelong Learning Oversight Committee, Science and Quality Committee, Governance Committee, Practice Administrator Workgroup and as an advisor for the ACC’s Innovation Program.
Itchhaporia’s professional interests include quality measurement and improvement in cardiovascular disease, focusing on emerging risk factors and medical and lifestyle interventions to prevent coronary heart disease. She is also extensively involved in advancing technology and innovations that will advance the digital transformation of cardiovascular medicine to ultimately improve the lives of patients and clinicians, while helping to achieve health equity.
Itchhaporia’s professional passions have led to leadership roles in advancing the ACC’s strategic priorities, including serving as chair of the ACC Board of Trustees Health Equity Task Force, which addresses issues of health disparities, the social determinants of health and improving access to care for underserved patients. Further work toward health equity will be at the forefront of her presidential year.
“Health equity has been a priority for the College for a long time and for the first time we are feeling like this could be actualized,” Itchhaporia said. “In cardiology we need to have the mindset to prioritize health equity issues, and I’m excited that this is in our reach.”
She received her medical degree from St. Louis University School of Medicine and completed her residency in internal medicine at Stanford University Medical Center. She then joined the general medicine faculty at the University of California, San Francisco (UCSF), ultimately pursuing a cardiology fellowship at Georgetown University and an interventional cardiology fellowship at Stanford University.
Other ACC officers for 2021-2022 are Vice President Edward T. A. Fry, MD, FACC; Board of Governors Chair Joseph Marine, MD, FACC; and Treasurer Christopher M. Kramer, MD, FACC.
Dota 2 Patch 7.29 Will Reveal a New Hero
Pokemon GO announces details for Rivals Week
Drift0r Opens Up About Harassment By Eight Thoughts
Valorant Redeem Codes: How to redeem?
Wall Street-Riese BNY Mellon über das Bitcoin Stock to Flow-Model: „Mehr Kunst als Wissenschaft“
MicroStrategy kauft weitere 253 BTC für 15 Millionen US-Dollar
Bitcoin Miner hodln ihre BTC anstatt sie zu verkaufen
Call of Duty streamer and host TeePee joins Envy Gaming
Reports suggest G2 Esports is reviewing its Valorant roster
How to watch the TFT Fates Championship
Best Warzone guns: the weapons you need to use in Black Ops Cold War Season 2
The top three weapons in Black Ops Cold War Season 2 Reloaded
Ludwig passes 200,000 Twitch subscribers, closes in on Ninja’s record
W33 Removed From Team Nigma’s Active Roster
Free Fire Redeem Codes for today [5th April]
Team Mahi’s owner Sentinel’s Nirbhaya Rape reference demands severe course correction
Playa del Carmen: Krypto-Hotspot mit HODLversity
Hexagrams and Wolf No Longer Casting the Overwatch League 2021
“Lost control,” TM Sentinel issues apology; seeks forgiveness for ‘disgraceful’ comments
Code S RO16: Bunny & Hurricane advance, TY & DRG eliminated
Esports1 week ago
Riot gives insight into Gwen’s origin and gameplay design process for League of Legends
Esports1 week ago
Everything you need to know about the 2021 Mid-Season Invitational
Blockchain7 days ago
Bitcoin Cash Price Prediction: BCH/USD Price Turns Bearish; Can the $540 Support Hold?
Esports1 week ago
Glitched Market 2K21: What is it and How to Unlock it
Esports1 week ago
Oddworld: Soulstorm, Days Gone, and Zombie Army 4 are PlayStation Plus’ free games for April
Blockchain7 days ago
How Chainlink will help secure Polkadot’s environment
Esports6 days ago
GeneRaL is replaced by RAMZES666 on Na’Vi
Blockchain7 days ago
Blockchain-based renewable energy marketplaces gain traction in 2021
Cleantech1 week ago
Volkswagen’s European Factories Up To 95% Powered By Renewables
Aviation1 week ago
World2Fly gears up for July launch with roll-out of Airbus A350-900
Cyber Security1 week ago
OPSWAT Secured $125 Million Growth Funding from Brighton Park Capital
PR Newswire1 week ago
Stärkung von Frauen in einer aufstrebenden Branche